Australia markets open in 39 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
321.02+5.74 (+1.82%)
At close: 04:00PM EST
321.00 -0.02 (-0.01%)
After hours: 05:16PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.44
52-week change 338.15%
S&P500 52-week change 3-7.17%
52-week high 3324.75
52-week low 3225.28
50-day moving average 3304.62
200-day moving average 3288.24

Share statistics

Avg vol (3-month) 31.49M
Avg vol (10-day) 31.63M
Shares outstanding 5256.69M
Implied shares outstanding 6N/A
Float 8256.05M
% held by insiders 10.19%
% held by institutions 196.78%
Shares short (29 Dec 2022) 42.5M
Short ratio (29 Dec 2022) 41.67
Short % of float (29 Dec 2022) 40.98%
Short % of shares outstanding (29 Dec 2022) 40.97%
Shares short (prior month 29 Nov 2022) 42.81M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 323 Aug 2000

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 37.62%
Operating margin (ttm)36.89%

Management effectiveness

Return on assets (ttm)13.68%
Return on equity (ttm)29.02%

Income statement

Revenue (ttm)8.7B
Revenue per share (ttm)34.05
Quarterly revenue growth (yoy)17.70%
Gross profit (ttm)3.62B
Net income avi to common (ttm)3.27B
Diluted EPS (ttm)12.73
Quarterly earnings growth (yoy)9.20%

Balance sheet

Total cash (mrq)9.77B
Total cash per share (mrq)38.06
Total debt (mrq)824.6M
Total debt/equity (mrq)6.33
Current ratio (mrq)4.70
Book value per share (mrq)50.77

Cash flow statement

Operating cash flow (ttm)4.05B
Levered free cash flow (ttm)2.47B